natgillin/translations-raw huggingface dataset:
Further especially preferred compositions according to the invention comprise as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide (compound A-1.2) and as component (B) a compound selected from azoxystrobin, picoxystrobin, fludioxonil, fenpropidin, fenpropimorph, fluopyram, difenoconazole, ipconazole, prothioconazole, tebuconazole, cyprodinil, chlorothalonil, epoxiconazole, propiconazole, cyproconazole, and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran izmedu slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
Atomiser according to one of the preceding claims, characterised in that the first and/or second locked state is not reversible, and/or that the pressurisation or atomisation is mechanically driven, in particular without propellant gas, preferably by spring power, and/or that the atomiser (1) is a portable inhaler, in particular for medicinal aerosol therapy. 
Raspršivač prema jednom od prethodnih zahtjeva, naznačen time, da so zatvoreno stanje ne može vratiti na početak, i/ili da se tlačenje ili raspršivanje provodi na čisto mehanički način, posebno bez pogonskog plina, HR P20131230 T1 poželjno pomoću snage opruge, i/ili da je raspršivač (1) konstruiran kao prijenosni inhalator, posebno za medicinsku aerosolnu terapiju.
R8A is selected from the group consisting of absent, hydrogen, an optionally substituted aryl and an optionally substituted heteroaryl; R9A is selected from the group consisting of NR30AR31A, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; 
A je odabran iz skupine koju čine po izboru supstituiran C1-24 alkil, po izboru supstituiran C2-24 alkenil, po izboru supstituiran C2-24 alkinil, po izboru supstituiran C3-6cikloalkil, po izboru supstituiran C3-6 cikloalkenil, NR30AR31A, po izboru supstituirana N-vezana aminokiselina i po izboru supstituiran derivat estera N-vezane aminokiseline;
an amount of K2O and/or Na2O, an amount of CaO and/or MgO, wherein the ratio of the amount of Al2O3 to the amount of SiO2 is in the range 0.34-0.73, wherein the ratio of the total amount of K2O and Na2O, to the total amount of CaO and MgO, is less than 1. 
Si0> u količini od 33 do 45 tež%, Al Oz u količini od 16 do 24 tež.%, Ti0> u količini od 0 do 3 tež.%, Fe, Oz u količini od 6 do 11 tež.%, CaO i MgO u ukupnoj količini od 23 do 33 vt%, i K20 i Na, O u ukupnoj količini od 1 do 6 tež.%.
Examples of compounds for the present invention include natural ecteinascidins, such as ecteinascidin 743 and other 1,4 bridged fused ecteinascidin compounds disclosed for example in U.S. Pat. Nos. 5,089,273, 5,478,932, 5,654,426, 5,721,362, 6,124,293, 5,149,804, U.S. Ser. No. 09/546,877, U.S. Pat. 
Primjeri spojeva za predstavljeni izum obuhvaćaju prirodne ekteinascidine, kao što je ekteinascidin 743 i drugel,4 premošćene fuzionirane spojeve ekteinascidina opisane npr. u US 5,089,273, US 5,478,932, US 5,654,426, US 5,721,362, US 6,124,293, US 5,149,804, US 09/546,877, US 5,985,876 i WO 01/77115.
Use of a compound or a pharmacologically acceptable salt thereof according to any one of claims 1 to 6 for producing a pharmaceutical composition for treating and/or preventing fibromyalgia. 
Uporaba spoja ili njegove farmakološki prihvatljive soli prema bilo kojem od zahtjeva 1 do 6 za proizvodnju farmaceutskog pripravka za liječenje i/ili prevenciju fibromialgije. hept-3-en-6-iljoctena kiselina; hept-3-en-6-iljoctena kiselina; lo
The method of claim 26, further comprising the step of reacting 2-amino-6-nitrobenzoic acid with an activated acetic acid in a solvent to form 2-methyl-5-nitro-4H-benzo[d][1,3]oxazin-4-one before reacting 2-methyl-5-nitro-4H-benzo[d][1,3]oxazin-4-one with 3-aminopiperidine-2,6-dione or a salt thereof. The method of claim 38, wherein the activated acetic acid is acetyl chloride or acetic anhydride. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 11 do 13, naznačen time što dodatno uključuje korak reakcije 2-amino-6-nitrobenzojeve kiseline s aktiviranom octenom kiselinom u otapalu kako bi se dobilo 2-metil-5-nitro- 4H-benzol[d][1,3]oksazin-4-on, prije reakcije 2-metil-5-nitro-4H-benzol[d][1,3]oksazin-4-ona s 3-aminopiperidin2,6-dionom, ili njegovom solju; po mogućnosti gdje je aktivirana octena kiselina acetil-klorid ili acetanhidrid.
reacting 9a-hydroxyandrost-4-en-3,17-dione 1 with H2 under hydrogenation conditions to form compound 2 
HO" navedena metoda sadrži: a) Reakciju 9a-hidroksiandrost-4-en-3,17-diona 1 s H> pod hidrogenirajućim uvjetima za dobivanje spoja 2; 10
1-12 % disintegrant, and 0.1-3 % lubricant, wherein the first and the second diluents are selected from the group consisting of cellulose powder, dibasic calciumphosphate anhydrous, dibasic calciumphosphate dihydrate, erythritol, low substituted hydroxypropyl cellulose, mannitol, pregelatinized starch or xylitol, 
-3 % sredstva za podmazivanje, naznačeno time da su prvo i drugo otapalo odabrani iz skupine sastavljene od celuloznog praška, bezvodnog dibazičnog kalcijevog fosfata, dibazični kalciju fosfata dihidrata, eritritola, slabo supstituirane hidroksipropil celuloze, manitola, preželatinizirani škroba ili ksilitola, pri čemu je najmanje jedan od prvog i drugog otapala dibazični kalcij fosfat bezvodan, i pri čemu je farmaceutski pripravak u farmaceutskom obliku filmom obložene tablete koja sadrži 2-4% filmske obloge.
reacting carbon tetrachloride with ethylene in the presence of iron chlorides, iron metal, and a trialkylphosphate in a reactor to produce a crude product comprising 1,1,1,3-tetrachloropropane; 
(i) reakciju ugljik tetraklorida s etilenom u prisutnosti željezovih klorida, metala željeza i trialkilfosfata radi dobivanja sirovog proizvoda koji sadrži 1,1,1,3-tetrakloropropan;
The filter was washed with 0.25x PBS, 30 µl MicroScint was added per well, and the bound radiolabel was quantitated by scintillation counting on a Packard TopCount Scintillation Counter. 
Filter je bio ispran sa 0.25x PBS, 30 ul MicroScint je dodano po izvoru i količina vezane radiooznake određena je mjerenjem scintilacije primjenom uređaja Packard TopCount Scintillation Counter.
Forage is diagrammatically illustrated passing through an internal conveyor 9 of the chopper in the direction indicated by the arrow 8 in Figure 2. 
Stočna hrana je shematski prikazana kako prolazi kroz interni transporter 9 uređaja za rezanje u smjeru strelice 8 na slici 2.
Figure 12 shows the drop in SDS concentration during diafiltration. 
Slika 12 pokazuje pad u SDS koncentraciji za vrijeme diafiltracije.
is selected from the group consisting of hydrogen, and methyl; and 
R, je odabran iz skupine koju čine vodik i Cy-Cgalkil;
A composition according to claim 1 wherein said carboxyvinyl polymer is carbomer, said galactomannan is guar, said borate is boric acid, and said sparingly soluble particulate compound is nepafenac at a concentration of 0.1 to 1.0 w/v%. 
Sastav prema zahtjevu 1, naznačen time, da navedeni karboksivinilni polimer je karbomer, navedeni galaktomanan je guar, navedeni borat je borna kiselina, i navedeni teško topivi spoj lebdećih čestica je nepafenak s koncentracijom od 0,1 do 1,0 % (masa/volumen).
a characteristic of plasticity i.e. deformation of the surface according to the shape of the body that executes pressure thereon, 
- < svojstvo plastičnosti odnosno deformacije površine prema obliku tijela koje na njega vrši pritisak,
It is clear that through the A3÷A4 phases it is possible for example to check the condition of the patient to which the bag is going to be delivered, and/or to check the bag's expiry date, in order to allow only secure and permitted operations. 
Jasno je da je kroz faze A3+A4 moguće, na primjer, ispitati stanje pacijenta kojemu se treba isporučiti vrećica, i/ili ispitati datum istjecanja roka vrećice, da bi se omogućili samo sigurni i dopušteni postupci.
Key blank 10 may have a generally elongate shaft portion 12 extending along a longitudinal axis 13 and defining first and second generally flat oppositely directed side surfaces 14 and 16, joined by edge surfaces 18 . 
Prazan ključ 10 može imati općenito izduženi trupni dio 12 koji se pruža duž uzdužne osi 131 definira prvu i drugu obično ravnu površinu 14 i 16 koje su okrenute na suprotne strane i spojene rubnim površinama 18.
Heating to this temperature endows the xylitol with non-crystalline characteristics. 
Zagrijavanje do ove temperature osigurava ksilitolu ne-kristalne osobine.
The composition of any preceding embodiment, wherein the composition does not include any mercurial material. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da sastav ne uključuje materijale koji sadrže živu.
The compound or salt for use according to claim 16, wherein said myeloproliferative disorder is chronic myelogenous leukemia (CML). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj kronična mijeloična leukemija (CML).
letting go of the portion of hair; 
otpuštanje dijela kose;
An apparatus according to any of claims 1 to 3, wherein said push-pull-turn hose (5) is in fluidic connection with the interior of the inflatable bladder (110) via a conduit (25) in the proximal collar fitting (3). 
Uređaj prema bilo kojem od zahtjeva od 1 do 3, naznačen time da je spomenuto crijevo za potiskivanjepovlačenje-okretanje (5) protočno povezano s unutrašnjosti mjehura koji se napuhuje (110) preko voda (25) u proksimalnoj spojnici (3).
A system according to claim 12, wherein the composition has an operating characteristic of superheat during refrigeration in the range of: 
Sustav prema zahtjevu 12, naznačen da je temperatura isparivača u rashladnom sustavu u rasponu od ispod 0%C
The composition of any one of the preceding claims, wherein the alkalizing agent is an alkali or earth alkali hydroxide, an alkali or earth alkali carbonate, an alkali or earth alkali hydrogen carbonate, a phosphate, a glucosamine or a mixture of two or more of these compounds, preferably sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, sodium phosphate or a mixture of two or more of these components, more preferably sodium carbonate. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da sredstvo za alkalizaciju je alkalijski ili zemnoalkalijski hidroksid, alkalijski ili zemnoalkalijski karbonat, alkalijski ili zemnoalkalijski hidrogenkarbonat, fosfat, glukozamin ili mješavina od dva ili više tih spojeva, poželjno je to natrijev hidroksid, natrijev karbonat, natrijev hidrogenkarbonat, natrijev fosfat ili mješavina od dva ili više tih sastojaka, a najpoželjniji je natrijev karbonat.
a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein: 
5 njegov stereoizomerni oblik, farmaceutski prihvatljiva sol, solvat ili polimorf koji sadrže mono- ili di-supstituiranu indolnu skupinu; navedeni spoj je odabran iz skupine gdje:
at least one antiepileptic selected from the group consisting of pregabalin and gabapentin. 
barem jedno antiepileptičko sredstvo odabrano iz skupine koja sadrži topiramat, lamotrigin, karbamazepin, lakozamid, levetiracetam i retigabin.
The method of claim 17, wherein the therapeutically effective amount of crenolanib or a salt thereof is also provided prophylactically at effective amounts are from about 50 to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day, 350 to 500 mg per day, or 400 to 500 mg per day. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu se terapijski djelotvorna količina crenolaniba ili njegove soli daje profilaktički u djelotvornoj količini od 50 do 500 mg dnevno, od 100 do 450 mg dnevno, od 200 do 400 mg dnevno, od 300 do 500 mg dnevno, od 350 do 500 mg dnevno ili od 400 do 500 mg dnevno.
In another embodiment, the (±)-A9-THC obtained in the Crystallizing Step comprises at least about 98% by weight of trans-(-)-A9-THC and trans-(+)-A9-THC based on the total amount of cannabinoids. 
Postupak prema zahtjevu 1, naznačen time da sastav trans-(-)-A*-tetrahidrokanabinola sadrži najmanje oko 98% težinski trans-(-)-A"-tetrahidrokanabinola bazirano na ukupnoj količini od trans-(-)-A-tetrahidrokanabinola i trans-
Said Asian style of veneer manufacturing requires an integrated process. 
Navedeni azijski način proizvodnje furnira zahtjeva integrirani postupak.
Ship with vertical draught system according to the previous claims characterised in that the hulls (1, 1') comprise a plurality of flood siphons in the compartments for submerging them. 
Brod s vertikalnim gazom sukladno ranijem zahtjevu naznačen time što trupovi (1,1’) obuhvaćaju više poplavnih sifona u odjeljcima za njihovo potapanje.
A compound of formula XII: where: 
Spoj formule XII:
client-side executing the method for estimating the perception quality of the transmitted audio signal according to any of claims 1 to 17; 
B) provođenja postupka procjene kvalitete opažanja prenesenog audio signala u skladu s bilo kojim od patentnih zahtjeva 1 do 13 sa strane klijenta;
Use as defined in claim 3, wherein the nuclear hormone receptor is an estrogen receptor, androgen receptor, progesterone receptor, thyroid hormone receptor, glucocorticoid receptor or retinoic acid receptor. 
Upotreba u skladu s patentnim zahtjevom 3, naznačena time što je nuklearni hormonski receptor receptor estrogena, receptor androgena, receptor progesterona, receptor tireoidnog hormona, receptor glukokortikoidnog hormona ili receptor retinske kiseline.
The system of claim 1, wherein the face plate is a glass plate; and the base plate and the side plates are composite plates formed by plastic plates and insulation plates. 
Sustav iz bilo kojeg od zahtjeva 1-3, naznačen time, da je prednja ploča (1.4) staklena ploča; i osnovna ploča (1.5) i bočne ploče su kompozitne ploče formirane od plastičnih ploča i izolacijskih ploča.
amino acid residues at framework positions 24 and 94 of the variable heavy chain according to the Kabat numbering scheme are substituted, wherein the substituted amino acid at framework position 24 is alanine (A) and the substituted amino acid at framework position 94 is aspartic acid (D); and wherein the recombinant antibody molecule or the a4-binding fragment thereof binds VLA-4. 
(ii) aminokiselinski ostatci na okvirnim pozicijama 24 i 94 od varijabilnog jakog lanca prema shemi numeriranja Kabat, supstituirani s ne-humanim ostatcima, gdje ne-humani ostatak na okvirnoj poziciji 24 je alanin (A) i ne-humani ostatak na okvirnoj poziciji 94 je aspartna kiselina (D); i pritom se rekombinantna molekula protutijela ili njezin fragment koji veže a4, veže na VLA-4.
A pharmaceutical formulation comprising the crystalline salt of any one of claims 1 to 7 and a pharmaceutically acceptable carrier. 
Farmaceutska formulacija koja obuhvaća kristalnu sol iz bilo kojeg od patentnih zahtjeva 1 do 7 i farmaceutski prihvatljiv nosač.
depositing a second layer of resin paste from the second doctor box onto a second carrier film; 
nanošenje drugog sloja paste od smole (14) iz drugog spremnika za izjednačavanje (16) na drugi nosač (26);
In some embodiments, (such as, for example, Compound_1, Compound_5, and Compound_6) provided are 19-mer double-stranded nucleic acid molecules wherein the antisense strand is SEQ ID NO:127 and the sense strand is SEQ ID NO:60. In certain embodiments, provided are 19-mer double-stranded nucleic acid molecules wherein the antisense strand is SEQ ID NO:127 and includes 2′OMe modified ribonucleotides; a 2′-5′-ribonucleotide in at least one of positions 1, 5, 6, or 7; and a non-nucleotide moiety covalently attached to the 3′-terminus; and the sense strand is SEQ ID NO:60 and includes at least one 2′-5′-ribonucleotide or 2′OMe modified ribonucleotide; a non-nucleotide moiety covalently attached at the 3′-terminus; and a cap moiety covalently attached at the 5′-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2'-0- metilom modificirane ribonukleotide; 2'-5'-ribonukleotid na najmanje jednom od položaja 1, 5, 6, ili i nenukleotidni ostatak kovalentno vezan na 3'-kraju; te gdje smisleni lanac dodatno sadrži najmanje jedan 2/'-5'- ribonukleotid ili 2'-O-metilom modificirani ribonukleotid; nenukleotidni ostatak kovalentno vezan na 3'-kraju; i ostatak koji vrši ulogu kape kovalentno vezan na 5'-kraju.
The feed stock of item 1, wherein the sorbent is selected from the group consisting of sodium sesquicarbonate (Trona), sodium bicarbonate, sodium carbonate, zinc ferrite, zinc copper ferrite, zinc titanate, copper ferrite aluminate, copper aluminate, copper managanese oxide, nickel supported on alumina, zinc oxide, iron oxide, copper, copper (I) oxide, copper (II) oxide, limestone, lime, Fe, FeO, Fe2O3, Fe3O4, iron filings, CaCO3, Ca(OH)2, CaCO3·MgO, silica, alumina, china clay, kaolinite, bauxite, emathlite, attapulgite, coal ash, egg shells, and Ca-montmorillonite. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, ili modificirano zamjensko gorivo u skladu s bilo kojim patentnim zahtjevom 3 do 7, naznačeno time, da su dva ili više sorbensa odabrana iz skupine koju čine: trinatrij hidrogendikarbonat dihidrat (Trona), natrijev bikarbonat, natrijev karbonat, cinkov ferit, cink-bakar ferit, cinkov titanat, bakar-ferit aluminat, bakrov aluminat, bakar-oksid mangan, nikal na glini, cinkov oksid, željezni
Kit for the prediction of the chance of a successful pregnancy, comprising: 
Komplet za predviđanje vjerojatnosti za uspješnu trudnoću, naznačen time da sadrži: a.
treat intolerance to said allergen in a subject wherein said probiotic and food allergen are to be administered sequentially or simultaneously to said subject; 
(a) liječenje intolerancije na spomenuti alergen kod subjekta pri čemu se navedeni probiotik 1 alergen hrane primenjuju sekvencijalno ili simultano kod spomenutog subjekta;
the absolute value of the zeta potential is less than about 30 mV, optionally wherein the absolute value of the zeta potential is less than about 10 mV. 
HR P20191400 T1 f) apsolutna vrijednost zeta potencijala je manja od oko 30 mV, pri čemu je apsolutna vrijednost zeta potencijala opcijski manja od oko 10 mV.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound mandipropamid. 
spoja formule (I) [image] naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i spoj mandipropamid.
In yet further embodiments of the above embodiment, the antigen binding fragment is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a scFv, a di-scFv, a bi-scFv, a tandem (di, tri)-scFv, a Fv, a sdAb, a tri-functional antibody, a BiTE, a diabody and a triabody. 
Postupak prema patentnom zahtjevu 1, naznačen time da je protutijelo fragment veznog antigena, po mogućnosti takvog da je fragment veznog antigena Fab fragment, Fab' fragment, F(ab'), fragment, scFv, di-scFv, bi-scFv, tandem (di, tri)-scFv, Fv, sdAb, tri-funkcionalno protutijelo, BiTE, dia-tijelo ili tria-tijelo.
is halogen or C1-C6 alkyl wherein said C1-C6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH2 units of said C1-C6 alkyl may be replaced with —O—; p is an integer from 0 to 3 inclusive; and 
R* je halogen ili C,-C4 alkil gdje je navedeni C,-C4 alkil supstituiran s 0-6 halogena i gdje do dvije nesusjedne CH jedinice navedenog Ci-Cg alkila mogu biti zamijenjene s -O-; HR P20170787 T1 p je cijeli broj koji uključuje od 0 do 3; i
The powder composition according to claim 1, further comprising sodium citrate or citric acid. 
Pripravak u skladu s patentnim zahtjevom 3, naznačen time što je aditiv limunska kiselina ili natrijev citrat.
The slurry of claim 1 wherein the aluminum or aluminum alloy powder comprises a particle size distribution characterized in that the 50 th percentile of the particle size distribution has a diameter of between about 4 to 7 microns and the 90th percentile of the particle size distribution has a diameter of less than or equal to about 11.5-15.5 microns. 
Gusta smjesa iz patentnog zahtjeva 1 ili 3, pri čemu aluminij ili prah aluminijeve slitine obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 4 i 7 mikrometara (mikrona) i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 11.5-15.5 mikrometara.
The method according to claim 2, wherein the data concerning the blood contained in the bag are cross-checked with corresponding data present in the external data-management system. 
Postupak u skladu s patentnim zahtjevom 3, kod kojega su podaci koji se odnose na krv koja je sadržana u vrećici unakrsno ispitani s odgovarajućim podacima koji su prisutni u vanjskom sustavu za vođenje podataka (17).
Preferably, He dosage increase is rapid so as to achieve efficacy in as short a time as possible, while minimizing adverse effects of too high an initial dose of buprenorphine. 
Preferira se da je povećavanje doze toliko brzo da se postigne učinkovitost u što kraćem vremenu, ali da se u isto vrijeme minimaliziraju štetni učinci previsoke početne doze buprenorfina.
is hydrogen, or C1-C6 alkyl optionally substituted by hydroxy; 
R1 je vodik, ili Ci-Cg alkil prema potrebi supstituiran s hidroksi;
Thus when R2 together with R3 together with the nitrogen atom to which they are attached form a saturated 5 or 6 membered heterocyclic ring which optionally contains additional heteroatoms, this suitably comprises a morpholine ring. 
Dakle, kada R* i R*, zajedno sa dušikovim atomom na kojeg su vezani, tvore zasićeni petero- ili šestero- člani heterociklički prsten koji opcionalno sadržava dodatne heteroatome, tada taj prsten prikladno uključuje morfolinski prsten.
The results are summarized in Figures 6,7 and 8. 
Rezultati su prikazani na slikama 6, 7 i 8.
The pH was adjusted to 4 with NaOH (aq., conc.), this gave a heavy precipitation and the solids were removed by filtration, washed with water and dried in vacuo. 
HR P20070194 T3 se doda. pH se namjesti do 4 sa NaOH (vod., konc.), pri čemu dolazi do jakog taloženja i krutine se uklanjaju filtracijom, ispiru s vodom i suše u vakuumu.
The formulation of claim 2, wherein the chelating agent is edetate disodium, which is preferably present in an amount of 0.06%wt. 
Formulacija prema zahtjevu 2, naznačena time, da navedeno sredstvo za keliranje je etilendiamintetraoctena kiselina (EDTA), koja je poželjno prisutna u količini od 0.06% tež.
The transgenic plant of claim 1, said plant further comprising DNA encoding a Cry1Ab core toxin-containing protein. 
Transgena biljka prema zahtjevu 1, naznačena time, da navedena biljka nadalje obuhvaća DNK koja kodira protein Cry 1Ab koji u jezgri sadrži toksin.
An antibody comprising: the variable light chain sequence of SEQ ID NO: 85 and variable heavy chain sequence of SEQ ID NO: 99; 
(a) varijabilno područje slabog lanca od sekvence SEQ ID NO: 85, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 99;
The antigen binding protein or the composition of claim 10, wherein the inflammatory condition is selected from the group consisting of allergic asthma, allergic rhinosinusitis, allergic conjunctivitis, and atopic dermatitis. 
Sastav za uporabu u skladu s patentnim zahtjevom 11, pri čemu je upalno stanje odabrano iz grupe koja se sastoji od alergijske astme, alergijskog rinosinusitisa, alergijskog konjuktivitisa i atopijskog dermatitisa.
The process of claim 3, wherein the amount of calcium in the free DOTA, water, and meglumine used in steps b) and d) is less than 50 ppm. 
PPI i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu, odnosno u kelatnom prahu, naročito DOTA, vodi i megluminu, manja od 50 ppm, poželjno manja od 20 ppm.